Login / Signup

Therapeutic Window of Clopidogrel and Ticagrelor in Patients With Critical Limb-Threatening Ischemia.

Ashwat S DhillonJorge CaroHan TunDavid G ArmstrongVincent RoweDavid M ShavelleLeonardo C Clavijo
Published in: Journal of cardiovascular pharmacology and therapeutics (2019)
Although ticagrelor has been proposed as an alternative for patients with HPR on clopidogrel, the current study observes an excess of platelet inhibition with ticagrelor in most patients with CLTI at a dose of 90 mg twice daily.
Keyphrases